There are already several preclinical studies on tumor stroma targeting strategies, such as inhibition of TGF-β signaling, fibroblast growth factor (FGF) pathway, focal adhesion kinase (FAK), and CXC-chemokine receptor 4 [8]. This evidence concerns the gene TGFB1 and neoplasm.